A pharmacophore model for PDE IV inhibitors

被引：10
|
作者：
Polymeropoulos, EE
Hofgen, N
机构：
[1] Department of Chemical Research, Corporate R and D, ASTA Medica Group, D-60314, Frankfurt
来源：
QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIPS | 1997年 / 16卷 / 03期
关键词：
PDE IV Inhibitors; asthma; pharmacophore; rolipram analogs; xanthine analogs; nitraquazone analogs; GRID calculations; molecular modelling;
D O I：
10.1002/qsar.19970160307
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
Based on conformational analysis and GRID-contour calculations we developed a common primary pharmacophore for rolipram analog, nitraquazone and xanthine derivative PDE IV inhibitors. In spite of the structural differences exhibited by the three substance classes we could provide evidence that they share common hydrogen bonding and lipophilic enzyme binding sites.
引用
收藏
页码：231 / 234
页数：4
相关论文
共 50 条
  • [1] A three-dimensional pharmacophore model for dipeptidyl peptidase IV inhibitors
    Lu, I-Lin
    Tsai, Keng-Chang
    Chiang, Yi-Kun
    Jiaang, Weir-Torn
    Wu, Ssu-Hui
    Mahindroo, Neeraj
    Chien, Chia-Hui
    Lee, Shiow-Ju
    Chen, Xin
    Chao, Yu-Sheng
    Wu, Su-Ying
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2008, 43 (08) : 1603 - 1611
  • [2] Pharmacophore Model of Cruzain Inhibitors
    Malvezzi, Alberto
    de Rezende, Leandro
    T-do Amaral, Antonia
    QSAR & COMBINATORIAL SCIENCE, 2009, 28 (08): : 781 - 784
  • [3] The novel potent and selective PDE IV inhibitors
    Ukita, T
    Sugahara, M
    Terakawa, Y
    Kikkawa, H
    Wada, K
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1997, 213 : 91 - MEDI
  • [4] Pharmacophore model construction of β-secretase inhibitors
    Huang Wen-Hai
    Hu Chun-Qi
    Liao Yong
    Sheng Rong
    Hu Yong-Zhou
    ACTA CHIMICA SINICA, 2008, 66 (16) : 1889 - 1897
  • [5] The design and synthesis of bioavailable PDE IV inhibitors.
    Cox, PJ
    Fenton, G
    Newton, CG
    Page, K
    Palfreyman, MN
    Ratcliffe, AJ
    Smith, GF
    Souness, JE
    Stuttle, KAJ
    Thurairatnam, S
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1996, 212 : 115 - MEDI
  • [6] Emesis induced by inhibitors of type IV cyclic nucleotide phosphodiesterase (PDE IV).
    Robichaud, A
    Tattersall, FD
    Choudhury, I
    Rodger, IW
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 1998, 358 (01) : R661 - R661
  • [7] Synthetic studies on selective type IV phosphodiesterase (PDE IV) inhibitors.
    Takayama, K
    Iwata, M
    Okamoto, Y
    Aoki, M
    Niwa, A
    Isomura, Y
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1997, 214 : 245 - MEDI
  • [8] 8-Arylquinolines derivatives as potent PDE IV inhibitors
    Lacombe, P
    Deschênes, D
    Dubé, D
    Dubé, L
    Gallant, M
    Macdonald, D
    Mastracchio, A
    Perrier, H
    Huang, Z
    Laliberté, F
    Mancini, JA
    Masson, P
    Salem, M
    Nicholson, DW
    Girard, Y
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2005, 230 : U2672 - U2672
  • [9] Pharmacophore model of ALS inhibitors by DISCO method
    Maio, FM
    Su, HQ
    Wang, JL
    ACTA PHYSICO-CHIMICA SINICA, 2000, 16 (10) : 926 - 931
  • [10] In silico design and discovery of novel PDE-IV inhibitors
    Jabeen, Farukh
    Pillai, Girinath
    Hall, Charles
    Katritzky, Alan
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2015, 250
12345